SQI Diagnostics Inc V.SQD.H

Healthcare Medical Devices

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its RALI-Dx IL-6 Severity Triage Test and the RALI-fast IL-6 Severity Triage point of care (POC) Test each help clinicians identify which patients with SARS-CoV-2 are predicted to have a severe inflammatory response and should or should not be admitted to the hospital. Its RALI-Dx delivers results from the lab in less than an hour while RALI-fast delivers results at the patient point-of-care in about 15 minutes. The Company’s TORdx LUNG Test measures inflammation at the molecular level to assess the health of the donor lung. The Company is also focused on its organ transplant pipeline of products.

TSXV:SQD.H - Post by User

SQI Diagnostics Inc > IMPORTANT HIGHLIGHTS - MAY 12 INVESTOR DECK & RECENT AIF

<< Previous

Bullboard Posts

Next >>

Comment by FactFinder1994on May 19, 2022 10:36pm

100 Views

Post# 34697226

RE:RE:IMPORTANT HIGHLIGHTS - MAY 12 INVESTOR DECK & RECENT AIF

I like your math.....Now take it Global....
Additional food for thought here too...

1) RALI-Dx (all things respiratory) tests

2) TOR-Dx for transplants at $10K per Lung assessment, knowing that after Lungs there will be Kidney, Liver, Heart etc to follow

3) EXACT Covid-19 Antibody test

4) A grab-bag of other tests, proprietary technology and patents, including "smart surface", with the ability to license out same

Each one of these four categories individually has the ability to exceed a billion dollars in revenue, especially when you think globally.

These are all high margin scenarios, so it isn't hard to understand why Barrons has a $6 target. There are very few of us that grasp the opportunity here and when word gets out it will be wild. Even this late in the game, this company remains a near secret. I'm not sure if its next week, next month, or next quarter, but a substancial move up in value is long overdue.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing